Spero Therapeutics Statistics
Share Statistics
Spero Therapeutics has 55.91M
shares outstanding. The number of shares has increased by 0.98%
in one year.
| Shares Outstanding | 55.91M |
| Shares Change (YoY) | 0.98% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 28.97% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 57 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 801.3K, so 1.47% of the outstanding
shares have been sold short.
| Short Interest | 801.3K |
| Short % of Shares Out | 1.47% |
| Short % of Float | 1.78% |
| Short Ratio (days to cover) | 3.22 |
Valuation Ratios
The PE ratio is -0.81 and the forward
PE ratio is -1.16.
Spero Therapeutics's PEG ratio is
0.
| PE Ratio | -0.81 |
| Forward PE | -1.16 |
| PS Ratio | 2.03 |
| Forward PS | 0.3 |
| PB Ratio | 1.21 |
| P/FCF Ratio | -2.37 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Spero Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.19,
with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.19 |
| Quick Ratio | 2.19 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | -0.18 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $856,125 |
| Profits Per Employee | $-2,142,687.5 |
| Employee Count | 32 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -65.27% in the
last 52 weeks. The beta is 0.23, so Spero Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.23 |
| 52-Week Price Change | -65.27% |
| 50-Day Moving Average | 0.72 |
| 200-Day Moving Average | 1.05 |
| Relative Strength Index (RSI) | 31.73 |
| Average Volume (20 Days) | 128,146 |
Income Statement
In the last 12 months, Spero Therapeutics had revenue of 27.4M
and earned -68.57M
in profits. Earnings per share was -1.27.
| Revenue | 27.4M |
| Gross Profit | 27.39M |
| Operating Income | -73.36M |
| Net Income | -68.57M |
| EBITDA | -72.48M |
| EBIT | -72.48M |
| Earnings Per Share (EPS) | -1.27 |
Full Income StatementBalance Sheet
The company has 52.89M in cash and 4.3M in
debt, giving a net cash position of 48.59M.
| Cash & Cash Equivalents | 52.89M |
| Total Debt | 4.3M |
| Net Cash | 48.59M |
| Retained Earnings | -459.64M |
| Total Assets | 110.54M |
| Working Capital | 58.2M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -23.44M
and capital expenditures 0, giving a free cash flow of -23.44M.
| Operating Cash Flow | -23.44M |
| Capital Expenditures | n/a |
| Free Cash Flow | -23.44M |
| FCF Per Share | -0.43 |
Full Cash Flow StatementMargins
Gross margin is 99.99%, with operating and profit margins of -267.78% and -250.28%.
| Gross Margin | 99.99% |
| Operating Margin | -267.78% |
| Pretax Margin | -250.28% |
| Profit Margin | -250.28% |
| EBITDA Margin | -264.57% |
| EBIT Margin | -267.78% |
| FCF Margin | -85.57% |
